- Home
- CAL vs ORKA Comparison
CAL vs ORKA Comparison
Compare CAL & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAL
- ORKA
- Stock Information
- Founded
- CAL 1878
- ORKA 2004
- Country
- CAL United States
- ORKA United States
- Employees
- CAL N/A
- ORKA N/A
- Industry
- CAL Shoe Manufacturing
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CAL Consumer Discretionary
- ORKA Health Care
- Exchange
- CAL Nasdaq
- ORKA Nasdaq
- Market Cap
- CAL 446.5M
- ORKA 354.2M
- IPO Year
- CAL N/A
- ORKA N/A
- Fundamental
- Price
- CAL $14.69
- ORKA $14.21
- Analyst Decision
- CAL Hold
- ORKA Strong Buy
- Analyst Count
- CAL 1
- ORKA 8
- Target Price
- CAL $14.00
- ORKA $39.71
- AVG Volume (30 Days)
- CAL 871.4K
- ORKA 360.1K
- Earning Date
- CAL 05-29-2025
- ORKA 08-15-2025
- Dividend Yield
- CAL 1.90%
- ORKA N/A
- EPS Growth
- CAL N/A
- ORKA N/A
- EPS
- CAL 2.43
- ORKA N/A
- Revenue
- CAL $2,677,706,000.00
- ORKA N/A
- Revenue This Year
- CAL N/A
- ORKA N/A
- Revenue Next Year
- CAL $3.48
- ORKA N/A
- P/E Ratio
- CAL $6.08
- ORKA N/A
- Revenue Growth
- CAL N/A
- ORKA N/A
- 52 Week Low
- CAL $12.09
- ORKA $5.49
- 52 Week High
- CAL $44.51
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- CAL 58.35
- ORKA N/A
- Support Level
- CAL $12.14
- ORKA N/A
- Resistance Level
- CAL $15.02
- ORKA N/A
- Average True Range (ATR)
- CAL 0.67
- ORKA 0.00
- MACD
- CAL 0.30
- ORKA 0.00
- Stochastic Oscillator
- CAL 88.74
- ORKA 0.00
About CAL Caleres Inc.
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.